Published online December 29, 2008
PEDIATRICS Vol. 123 No. 1 January 2009, pp. 1-5 (doi:10.1542/peds.2008-0200)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bloch, J.
Right arrow Articles by Scherrer, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bloch, J.
Right arrow Articles by Scherrer, U.
Related Collections
Right arrow Office Practice
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

ARTICLE

Prevalence and Time Course of Acute Mountain Sickness in Older Children and Adolescents After Rapid Ascent to 3450 Meters

Jonathan Bloch, MDa, Hervé Duplain, MDa, Stefano F. Rimoldi, MDb, Thomas Stuber, MDb, Susi Kriemler, MDc, Yves Allemann, MDb, Claudio Sartori, MDa and Urs Scherrer, MDa

a Botnar Center for Extreme Medicine, Department of Internal Medicine, University Hospital, Lausanne, Switzerland
b Swiss Cardiovascular Center Bern, University Hospital, Bern, Switzerland
c Institute of Exercise and Health Sciences, University of Basel, Basel, Switzerland

OBJECTIVE. Acute mountain sickness is a frequent and debilitating complication of high-altitude exposure, but there is little information on the prevalence and time course of acute mountain sickness in children and adolescents after rapid ascent by mechanical transportation to 3500 m, an altitude at which major tourist destinations are located throughout the world.

METHODS. We performed serial assessments of acute mountain sickness (Lake Louise scores) in 48 healthy nonacclimatized children and adolescents (mean ± SD age: 13.7 ± 0.3 years; 20 girls and 28 boys), with no previous high-altitude experience, 6, 18, and 42 hours after arrival at the Jungfraujoch high-altitude research station (3450 m), which was reached through a 2.5-hour train ascent.

RESULTS. We found that the overall prevalence of acute mountain sickness during the first 3 days at high altitude was 37.5%. Rates were similar for the 2 genders and decreased progressively during the stay (25% at 6 hours, 21% at 18 hours, and 8% at 42 hours). None of the subjects needed to be evacuated to lower altitude. Five subjects needed symptomatic treatment and responded well.

CONCLUSION. After rapid ascent to high altitude, the prevalence of acute mountain sickness in children and adolescents was relatively low; the clinical manifestations were benign and resolved rapidly. These findings suggest that, for the majority of healthy nonacclimatized children and adolescents, travel to 3500 m is safe and pharmacologic prophylaxis for acute mountain sickness is not needed.


Key Words: acute mountain sickness • altitude • adolescents • prevalence

Abbreviations: AMS—acute mountain sickness


Accepted Apr 4, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Arch. Dis. Child.Home page
E Scrase, A Laverty, J C D Gavlak, S Sonnappa, D Z H Levett, D Martin, M P W Grocott, and J Stocks
The Young Everest Study: effects of hypoxia at high altitude on cardiorespiratory function and general well-being in healthy children
Arch. Dis. Child., August 1, 2009; 94(8): 621 - 626.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. G. Slomiany, L. Dai, P. A. Bomar, T. J. Knackstedt, D. A. Kranc, L. Tolliver, B. L. Maria, and B. P. Toole
Abrogating Drug Resistance in Malignant Peripheral Nerve Sheath Tumors by Disrupting Hyaluronan-CD44 Interactions with Small Hyaluronan Oligosaccharides
Cancer Res., June 15, 2009; 69(12): 4992 - 4998.
[Abstract] [Full Text] [PDF]

eLetters:

Read all eLetters

Personal experience with AMS
Michael Cater, MD
Pediatrics Online, 21 Jan 2009 [Full text]